ARCH Venture Partners invests in the development of seed and early stage technology companies that have the potential to grow rapidly into successful businesses. ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. ARCH Ventures enjoys special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 120 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors. For more information visit www.archventure.com.
Bain Capital Ventures is the Boston-based venture capital arm of Bain Capital, whose affiliates manage over $50 billion of assets. Founded in 1984, Bain Capital and its affiliates have invested in over 230 companies with such notable successes as Doubleclick, Gartner Group and Staples. Bain’s history of investing in early stage companies also dates back to 1984, having made over 120 venture-stage investments since inception. In 2001, Bain Capital Ventures was formed as a separate arm of Bain Capital to focus exclusively on seed through late-stage growth investments in software, hardware, information, healthcare, and technology-driven business services companies. For more information visit www.baincapital.com.
A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2014, revenues reached €1.698 billion with 88% of sales outside of France.
bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. For more information visit: www.biomerieux.com.
Cormorant Asset Management
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabs™ which invents and launches transformative companies, and Venture Capital, which finances and develops innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team is active in three principal business sectors: therapeutics, health technologies and sustainability/clean technology. Past successful Flagship portfolio companies include: Accuri Cytometers (acquired by Becton, Dickinson and Company), Adnexus (acquired by Bristol-Myers Squibb), Hypnion (acquired by Eli Lilly), Agios (NASDAQ: AGIO), AVEO (NASDAQ: AVEO), BG Medicine (NASDAQ: BGMD), Receptos (NASDAQ: RCPT), Tetraphase (NASDAQ: TTPH), and Morphotek (acquired by Eisai). Additional notable portfolio companies include: Affinnova, BIND Therapeutics, Joule Unlimited, Quanterix, and Moderna Therapeutics. For more information, please visit www.flagshipventures.com.
Founded in 2007, Quanterix has developed an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today.
The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant commercial unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more.
Quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at Tufts University by Dr. David Walt, scientific founder of Quanterix and Illumina (NASDAQ: ILMN).
Recent Webcast Presentations
Quanterix at JP Morgan Healthcare Conference 2016
January 12, 2016
Quanterix at Stifel 2015 Healthcare Conference (Replay)
November 19, 2015
Recent Media Coverage
Quanterix In The News
01 Aug 2016Read More
Lexington, Mass. – August 1, 2016 — Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced a license agreement for research use with Banyan Biomarkers, a pioneering company in the development of biomarkers for traumatic brain injury (TBI). Quanterix’ Simoa platform will incorporate the Banyan UCH-L1™ and Banyan GFAP™ assays to help further neurological research for improved TBI diagnosis and treatment.
Frontage Laboratories Announces Partnership with Quanterix and Validation of Simoa HD-1 Analyzer and Software to Support Biomarker Analysis15 Jun 2016
Exton, PA – June 15, 2016 — Frontage Laboratories, Inc., a Contract Research Organization based in Pennsylvania, New Jersey and China, today announced that they are the first CRO to complete a GLP validation of the Simoa HD-1 Analyzer and software along with the interface to Watson LIMS. Data will be generated, processed and stored in a secure environment meeting the compliance requirements needed to support biomarker analysis for regulated studies.
24 May 2016Read More
Lexington, Mass. – May 24, 2016 — Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced that the Company’s CEO and Executive Chairman, Kevin Hrusovsky, will be presenting at the 5th Annual One Mind Summit, which takes place May 24-25, 2016, in Crystal City, VA.
Quanterix Opens Call for Proposals for Second Annual Accelerator Grant Program Focused on Oncology and Liquid Tumor Biopsy Technology18 Apr 2016
Lexington, Mass. – April 18, 2016 — Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced the recipient of its first annual Accelerator Grant Program and a call for proposals for its second grant, focused on oncology research. The state-of-the-art Simoa Accelerator Labis a dedicated laboratory environment for custom assay development and clinical sample testing. Since its launch in 2014, the Lab has grown from one to four instruments, expanding its capabilities to run up to 2,400 different samples a day.
23 Mar 2016Read More
Lexington, Mass. – March 23, 2016 — Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced it secured $46 million in Series D funding from both new and existing investors. This infusion of capital will allow Quanterix to build on the significant growth realized in the last two years. Proceeds will be used to develop desk-top instruments, expand the assay menu for protein and nucleic acid biomarkers, bolster the global channel to market and enable new, pivotal medical studies to be performed with Quanterix’ game changing technology, transforming life science research and diagnostics.
Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid β up to 90 Days after Traumatic Brain Injury.08 Jul 2016
Blood biomarkers indicate mild neuroaxonal injury and increased amyloid β production after transient hypoxia during breath-hold diving07 Jul 2016
An ultrasensitive assay format for detecting ULK1 inhibition by monitoring the phosphorylation status of Atg1304 Jul 2016
Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders25 Jun 2016
31 May 2016Read More
Investor Contact Information
Tel: +1 (617) 301-9400